Abstract

MiniMed Group, Inc. will report fiscal results on September 01, 2026, Pre-Mkt; this preview distills the latest quarterly expectations, segment dynamics, and what investors should watch across revenue, profitability, and EPS trends.

Market Forecast

Consensus for the current quarter anticipates revenue of 827.07 million US dollars, an adjusted EPS of 0.09, and EBIT of 36.57 million US dollars; growth interpretations imply revenue up 15.48% year over year, EPS down 18.82% year over year, and EBIT up 0.47% year over year. The market expects gross profit margin to remain resilient given last quarter’s 57.35%, while net profitability is projected to improve from a deep loss as operating leverage stabilizes.

The core business outlook centers on diabetes technologies, where sensors and pump ecosystems continue to anchor growth; the company’s product cycle and payer coverage underpin shipment pipelines and order visibility. The most promising segment is CGM, supported by recent volume traction and ecosystem attach rates that suggest robust repeat usage.

Last Quarter Review

MiniMed Group, Inc. reported last quarter revenue of 837.00 million US dollars, a gross profit margin of 57.35%, GAAP net profit attributable to shareholders of -185.00 million US dollars, a net profit margin of -22.10%, and adjusted EPS of -0.68; year-over-year comparisons for EPS and revenue were not disclosed by the company in the data set.

A notable development was the sharp sequential improvement trajectory implied for the current quarter, following a quarter that included heavy expense items and underutilization impacts weighing on net margin. From a business mix perspective, CGM led the portfolio by contribution, followed by consumables and pumps, reflecting a stable installed base and recurring revenue dynamics.

Current Quarter Outlook

Main business: Integrated diabetes management platform

The company’s core integrated platform—combining continuous glucose monitoring, insulin delivery, and connected software—is positioned to sustain double-digit revenue growth this quarter, with the market expecting 827.07 million US dollars, up 15.48% year over year. The prior quarter’s gross margin of 57.35% provides a high-quality base, with incremental upside if product mix tilts further to sensors and software-enabled features. While EPS is forecast to decline year over year by 18.82%, the stabilization in EBIT (up 0.47% year over year) suggests operating efficiency initiatives and moderation in promotional activity are beginning to offset inflationary and logistics pressures.

Execution priorities remain consistent: maintaining sensor availability, accelerating new patient starts, and improving adherence through app-led guidance and data insights. The company’s subscription-like revenue from sensors and disposables, paired with a growing installed base of pumps, should enhance revenue durability and predictable cash conversion as volumes scale. One sensitivity to monitor is the balance between volume growth and rebate/incentive intensity; maintaining pricing discipline while expanding access will be important to defend margins.

Most promising business: CGM ecosystem

CGM appears to be the growth fulcrum within the portfolio, benefiting from higher penetration among existing pump users and uptake in stand-alone use cases. Shipment cadence and recurring reorder rates are consistent with a durable growth runway, which underpins the market’s revenue growth expectation for the quarter. Attach rates into the broader therapy stack, including closed-loop or semi-automated dosing workflows, are pivotal for maintaining lifetime value well above customer acquisition costs.

From a profitability angle, CGM scale can amplify gross margin, given manufacturing learning curves and favorable overhead absorption. Continued enhancements in sensor wear time, accuracy, and user experience should support retention, while the digital layer creates differentiation that can reduce churn and support premium tiers. The performance of CGM this quarter will likely be the primary determinant of whether the company delivers the modest EBIT uptick implied by forecasts and narrows the gap toward consistent net profitability.

Stock price drivers this quarter

The first driver is operating leverage versus promotional intensity: investors will watch whether gross margin holds near the prior quarter’s 57.35% and whether SG&A growth moderates enough to translate revenue gains into positive EPS inflection. The second driver is CGM volume and adherence metrics, as these directly influence recurring revenue and gross margin mix; sustained reorder rates should validate the 15.48% revenue growth projection. The third driver is regulatory and product-cycle execution around connected features and algorithm updates, which can accelerate ecosystem lock-in and reduce price sensitivity; meaningful traction here could mitigate the year-over-year EPS decline of 18.82% implied by estimates.

Analyst Opinions

Cautious optimism prevails among recent institutional commentary, skewing bullish on revenue durability but guarded on earnings power near term. The majority view highlights revenue growth at approximately 15.48% year over year, with an expectation that CGM-led mix and tighter expense controls can lift EBIT to roughly 36.57 million US dollars. Analysts also emphasize that while EPS is forecast at 0.09, down 18.82% year over year, signs of operating normalization following last quarter’s significant net loss could signal a turn toward steadier profitability.

Well-followed analysts point to three themes underpinning the bullish stance: 1) a strengthening CGM franchise that benefits from repeat purchase behavior and rising penetration within both pump-attached and stand-alone cohorts, 2) improving visibility from the installed base that stabilizes consumable demand and supports forecasting accuracy, and 3) incrementally positive cost dynamics tied to scale and supply-chain normalization that support EBIT expansion even if list pricing remains competitive. The consensus is that execution on mix and cost control will be sufficient for the company to meet or slightly exceed top-line expectations, while EPS remains the swing factor dependent on operating leverage. If the company delivers stable gross margin near last quarter’s 57.35% and demonstrates discipline in SG&A, analysts believe shares could respond positively to confirmation of the EBIT improvement embedded in current estimates.